PPBT vs VERA

PPBT Core

Annual filing released 2025-03-10 · GPT 6 Luna

In December 2021, we decided to discontinue the manufacturing and distribution of Consensi. In February 2023, we completed the acquisition of Immunorizon, a privately held biotechnology company developing multi-specific antibodies as oncology therapies that selectively activate the immune response within the tumor microenvironment (TME). For information regarding the Immunorizon acquisition, see “Item 10 – Additional Information – C. Material Contracts – Immunorizon Acquisition.” For a description of our principal capital expenditures for the three years ended December 31, 2024, see “Item 5. Operating and Financial Review and Prospects.” B. Business Overview We are a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance.

A. Purple Biotech Ltd. (hereinafter: the “Company” or “Purple”) is a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance. The Company’s oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. CAPTN-3 is a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment.

VERA Core

Annual filing released 2025-02-28 · GPT 6 Luna

We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate, atacicept, a fully humanized TACI-Fc fusion protein that binds both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) and is self-administered subcutaneously, is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). We are conducting ORIGIN 3, the pivotal Phase 3 trial of atacicept 150 mg in IgAN, and in September 2024 completed enrollment of the initial cohort of 200 participants that will provide data for the 36-week urine protein creatinine ratio (UPCR) primary efficacy endpoint. We expect to announce primary endpoint results in the second quarter of 2025, supporting our planned submission for regulatory approval later in 2025.

1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS Description of Business Vera Therapeutics, Inc. (the Company) is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. The Company was incorporated in May 2016 in Delaware. The Company’s headquarters are in Brisbane, California. The Company operates in one segment, Therapeutics, focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Liquidity Since inception, the Company devoted substantially all of its resources to its research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.

PPBT Core

Annual filing released 2025-03-10 · GPT 6 Luna

In December 2021, we decided to discontinue the manufacturing and distribution of Consensi. In February 2023, we completed the acquisition of Immunorizon, a privately held biotechnology company developing multi-specific antibodies as oncology therapies that selectively activate the immune response within the tumor microenvironment (TME). For information regarding the Immunorizon acquisition, see “Item 10 – Additional Information – C. Material Contracts – Immunorizon Acquisition.” For a description of our principal capital expenditures for the three years ended December 31, 2024, see “Item 5. Operating and Financial Review and Prospects.” B. Business Overview We are a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance.

We are a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Our oncology pipeline includes CM24, NT219 and IM1240. In developing these therapeutic candidates, we aim to address both the tumor and the TME to potentially improve patient outcomes. For details regarding our oncology therapeutic candidates, see, “Item 4. Information on the Company – B. Business Overview.” In addition, our strategy is to pursue the acquisition of additional oncology therapeutic candidates at various stages of development to expand and diversify our portfolio and leverage our development capabilities. We currently do not have any binding material agreement or commitment to complete any transaction for the acquisition of new therapeutic candidates or approved drug products.

VERA Core

Annual filing released 2025-02-28 · GPT 6 Luna

We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate, atacicept, a fully humanized TACI-Fc fusion protein that binds both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) and is self-administered subcutaneously, is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). We are conducting ORIGIN 3, the pivotal Phase 3 trial of atacicept 150 mg in IgAN, and in September 2024 completed enrollment of the initial cohort of 200 participants that will provide data for the 36-week urine protein creatinine ratio (UPCR) primary efficacy endpoint. We expect to announce primary endpoint results in the second quarter of 2025, supporting our planned submission for regulatory approval later in 2025.

1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS Description of Business Vera Therapeutics, Inc. (the Company) is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. The Company was incorporated in May 2016 in Delaware. The Company’s headquarters are in Brisbane, California. The Company operates in one segment, Therapeutics, focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Liquidity Since inception, the Company devoted substantially all of its resources to its research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.

PPBT Core

Annual filing released 2025-03-10 · GPT 6 Luna

● CAPTN-3: A platform technology of conditionally activated tri-specific antibodies that engages both T cells and NK cells and a specific tumor-associated antigen (TAA) to induce a strong, localized immune response within the TME. A cleavable capping technology confines the compound’s therapeutic activity to the local TME, thereby potentially increasing the anticipated therapeutic window in patients.

Our CAPTN-3 tribody platform is comprised of conditionally activated tri-specific antibodies that engage both T cells and NK cells and a specific TAA to induce a strong, localized immune response within the TME. A cleavable capping technology confines the compound’s therapeutic activity to the local TME, which increases the anticipated therapeutic window in patients. This technology presents a novel mechanism of action by unleashing both innate and adaptive immune responses at the TME to induce an optimal anti-tumor immune response.

VERA Core

Annual filing released 2025-02-28 · GPT 6 Luna

Atacicept is a fully humanized fusion protein that is designed to modulate the B cell pathway, which has well characterized implications in immunologic diseases. Specifically, as shown in Figure 4 below, atacicept contains the soluble extracellular domain of the TACI receptor fused with the inactivated Fc domain of IgG1. TACI is a native receptor for BAFF and APRIL, members of the tumor necrosis factor family that promote B cell survival and autoantibody production associated with IgAN and other immunologic diseases. Dual blockade of BAFF and APRIL by TACI has been shown to be more potent than blocking BAFF alone or APRIL alone and has the benefit of targeting long-lived plasma cells, in addition to B cells, thus reducing production of Gd-IgA1 and its autoantibodies.

Therefore, atacicept is designed to precisely modulate B cell activity by binding both BAFF and APRIL, and follows a long history of impactful agents that are logically designed Fc fusion proteins. This mechanism acts directly on the source of IgAN, which we believe will significantly mitigate the downstream effects of the disease. Figure 4: Atacicept is the result of rational drug design Atacicept’s specific actions on IgAN disease pathogenesis are shown in Figure 5 below. Figure 5: Atacicept impact on IgAN pathogenesis (1)Atacicept inhibits BAFF and APRIL, leading to decreased Gd-IgA1 production by B cells. 8 (2)This leads to a reduction in the autoantibodies that bind to Gd-IgA1. (3)Therefore, formation of pathogenic immune complexes is greatly reduced. (4)This, in turn, reduces immune complex deposition in glomeruli and glomerular inflammation is reduced.

PPBT Core

Annual filing released 2025-03-10 · GPT 6 Luna

In December 2021, we decided to discontinue the manufacturing and distribution of Consensi. In February 2023, we completed the acquisition of Immunorizon, a privately held biotechnology company developing multi-specific antibodies as oncology therapies that selectively activate the immune response within the tumor microenvironment (TME). For information regarding the Immunorizon acquisition, see “Item 10 – Additional Information – C. Material Contracts – Immunorizon Acquisition.” For a description of our principal capital expenditures for the three years ended December 31, 2024, see “Item 5. Operating and Financial Review and Prospects.” B. Business Overview We are a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance.

We are a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Our oncology pipeline includes CM24, NT219 and IM1240. In developing these therapeutic candidates, we aim to address both the tumor and the TME to potentially improve patient outcomes. For details regarding our oncology therapeutic candidates, see, “Item 4. Information on the Company – B. Business Overview.” In addition, our strategy is to pursue the acquisition of additional oncology therapeutic candidates at various stages of development to expand and diversify our portfolio and leverage our development capabilities. We currently do not have any binding material agreement or commitment to complete any transaction for the acquisition of new therapeutic candidates or approved drug products.

VERA Core

Annual filing released 2025-02-28 · GPT 6 Luna

We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate, atacicept, a fully humanized TACI-Fc fusion protein that binds both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) and is self-administered subcutaneously, is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). We are conducting ORIGIN 3, the pivotal Phase 3 trial of atacicept 150 mg in IgAN, and in September 2024 completed enrollment of the initial cohort of 200 participants that will provide data for the 36-week urine protein creatinine ratio (UPCR) primary efficacy endpoint. We expect to announce primary endpoint results in the second quarter of 2025, supporting our planned submission for regulatory approval later in 2025.

1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS Description of Business Vera Therapeutics, Inc. (the Company) is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. The Company was incorporated in May 2016 in Delaware. The Company’s headquarters are in Brisbane, California. The Company operates in one segment, Therapeutics, focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Liquidity Since inception, the Company devoted substantially all of its resources to its research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.

PPBT Core

Annual filing released 2025-03-10 · GPT 6 Luna

In December 2021, we decided to discontinue the manufacturing and distribution of Consensi. In February 2023, we completed the acquisition of Immunorizon, a privately held biotechnology company developing multi-specific antibodies as oncology therapies that selectively activate the immune response within the tumor microenvironment (TME). For information regarding the Immunorizon acquisition, see “Item 10 – Additional Information – C. Material Contracts – Immunorizon Acquisition.” For a description of our principal capital expenditures for the three years ended December 31, 2024, see “Item 5. Operating and Financial Review and Prospects.” B. Business Overview We are a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance.

We are a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Our oncology pipeline includes CM24, NT219 and IM1240. In developing these therapeutic candidates, we aim to address both the tumor and the TME to potentially improve patient outcomes. For details regarding our oncology therapeutic candidates, see, “Item 4. Information on the Company – B. Business Overview.” In addition, our strategy is to pursue the acquisition of additional oncology therapeutic candidates at various stages of development to expand and diversify our portfolio and leverage our development capabilities. We currently do not have any binding material agreement or commitment to complete any transaction for the acquisition of new therapeutic candidates or approved drug products.

VERA Not tagged

Annual filing released 2025-02-28 · GPT 6 Luna

This activity has no positive tag in the selected filing snapshot.